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Abstract
Broncho-pulmonary neuroendocrine neoplasms (BP-NENs) are neoplasms orphan of an 
efficient therapy. Available medical treatments derived from clinical trials are not specific 
for the management of this malignancy. Sunitinib is a multi-receptor tyrosine-kinases 
(RTKs) inhibitor that has already shown its efficacy in NENs, but there are no available 
data about its action in BP-NENs. Therefore, our aim was to understand the effects of 
RTKs inhibition promoted by sunitinib in order to evaluate new putative targets useful 
in malignancy treatment. Since our results underlined a role for EGFR and IGF1R in 
modulating sunitinib antiproliferative action, we investigated the effects of erlotinib, an 
EGFR inhibitor, and linsitinib, an IGF1R inhibitor, in order to understand their function 
in regulating cells behaviour. Cell viability and caspase activation were evaluated on two 
immortalised human BP-NEN cell lines and primary cultures. Our results showed that 
after treatment with sunitinib and/or IGF1, EGF and VEGF, the antiproliferative effect of 
sunitinib was counteracted by EGF and IGF1 but not by VEGF. Therefore, we evaluated with 
AlphaScreen technology the phosphorylated EGFR and IGF1R levels in primary cultures 
treated with sunitinib and/or EGF and IGF1. Results showed a decrease of p-IGF1R after 
treatment with sunitinib and an increase after co-treatment with IGF1. Then, we assessed 
cell viability and caspase activation on BP-NEN cell lines after treatment with linsitinib  
and/or erlotinib. Results demonstrate that these two agents have a stronger 
antiproliferative effect compared to sunitinib. In conclusion, our results suggest that  
IGF1R and EGF1R could represent putative molecular targets in BP-NENs treatment.
Introduction
Neuroendocrine neoplasms (NENs) are neoplasms with 
an estimated annual incidence of 6.9/100,000 people 
in Europe per year, arising from cells of the diffuse 
endocrine system (DNES) (1, 2). NENs represent a wide 
group of malignancies originating from different parts of 
the human body. More than one half (about 70%) occurs 
in the gastrointestinal tract, while the other 25% occurs 
mostly in the broncho-pulmonary system (3, 4). NENs that 
affect the bronchial tree are called broncho-pulmonary 
NENs (BP-NENs) and represents approximately 25/30% of 
all NENs with an incidence of 1.2/100,000 people/year in 
European countries (5). The World Health Organization 
defines BP-NENs as an heterogeneous group that ranges 
from well-differentiated neoplasms characterised by an 
indolent behaviour to poorly differentiated forms with a 
high aggressive potential (6, 7, 8). The clinical management 
of BP-NENs needs a multidisciplinary approach but to 
date the only available curative treatment remains surgery 
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that is not feasible in most of the cases due to metastatic 
disease (6, 9, 10). Therefore, medical therapies, including 
chemotherapy, radiation, drugs acting on hormone 
receptors and molecular target therapy, gain a key role in 
the clinical management of BP-NENs (11). Chemotherapy 
and radiation have already been demonstrated to be 
ineffective in the treatment of BP-NENs, while somatostatin 
analogues have shown a great effect in controlling the 
eventual secretory pattern of carcinoids but not the ability 
of reducing the tumour mass (12, 13, 14). Recent studies 
have led to advances in the knowledge of the molecular 
mechanisms of NENs allowing the development of novel 
targeted therapies that are now included in daily clinical 
practice (1, 15). Everolimus and sunitinib are two targeted 
agents approved by the Food and Drugs Administration 
(FDA) for the treatment of different types of NENs (16). 
Everolimus is an mTOR inhibitor capable to slow down 
the tumour growth and arrest tumour cells proliferation; 
this agent has already been approved for renal cell 
carcinoma, breast cancer and neuroendocrine carcinomas 
such as gastroenteropancreatic and lung neuroendocrine 
neoplasms (17, 18, 19). Clinical trials have demonstrated 
that everolimus prolongs progression-free survival (PFS) 
in patients with advanced, nonfunctional, progressive 
NENs of lung or gastrointestinal origin. However, despite 
its initial efficacy, most of the patients exhibit progressive 
disease after a period of treatment (4, 20). Everolimus 
resistance can vary according to the patient and, in some 
cases, can be attributed to rebound AKT activation due to 
the activity of one of the two mTOR subunits: mTORC2 
complex (21, 22). Nonetheless, everolimus still represents 
the key therapeutic agent in the treatment of BP-NENs 
but, since patients can be insensitive or develop resistance 
after a period of treatment, there is an increasing need 
of new molecular targeted therapies (20). Sunitinib is 
a multi-tyrosine kinase growth factor receptor (RTKs) 
inhibitor indicated for the treatment of several NENs, 
such as gastrointestinal stromal tumours, advanced renal 
cell carcinoma and pancreatic neuroendocrine neoplasms 
(23). Its efficacy has been well described especially in 
pancreatic neuroendocrine tumours, due to the frequent 
overexpression of RTKs and the associated growth factors 
in this tumour (1, 24, 25, 26). Sunitinib was shown to have 
an anti-tumoural and antiangiogenic effect in patients 
with well-differentiated pancreatic NEN and to improve 
PFS of patients in a phase III clinical trial (3, 27). Despite 
its role in the treatment of pancreatic neuroendocrine 
neoplasms, there is still no clear evidence of its efficacy 
in NENs with a nonpancreatic origin as only few cases 
of BP-NENs were included in sunitinib’s previous trials 
(27, 28, 29). The lack of knowledge between the tumour 
type and drug efficacy highlights the importance of new 
in vitro studies useful to understand the possible role of 
sunitinib in BP-NENs treatment and find new potential 
molecular targets. Therefore, the aim of our study was to 
elucidate sunitinib’s mechanism of action in two BP-NEN 
cell lines and primary cultures, in order to identify new 
potential therapeutic targets in the treatment of BP-NENs. 
Moreover, we have also assessed whether other RTK 
inhibitors, erlotinib and linsitinib, could be effective in 
malignancy management.
Materials and methods
Drugs and chemicals
Sunitinib, erlotinib and linsitinib were purchased from 
Selleckchem. Compounds were dissolved in DMSO and 
stored at −80°C as 10 mM stock solutions.
EGF and IGF1 were purchased from ProSpec protein 
specialists (East Brunswick, NJ, USA); VEGF was purchased 
from Peprotech Inc (Rocky Hill, NJ, USA). EGF, IGF1 
and VEGF were resuspended in sterile PBS with 0.1% 
BSA. All other reagents, if not specified, were purchased 
from Sigma.
In vitro immortalised human cell lines
NCI-H727 and NCI-H720 cell lines, derived from human 
BP-NEN, were purchased from the American Type Culture 
Collection and were cultured in RPMI-1640 medium 
(Euroclone, Milan, Italy) supplemented with 10% fetal 
bovine serum, at 37°C in a humidified atmosphere with 
5% CO2. Experiments were performed within the seventh 
passage.
Cell viability
Variations in viable cell number were assessed using the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega). 
2 × 104 cells were seeded for each well in 96-well black 
plates, as previously described, and treated with sunitinib 
5 μM, linsitinib 5 μM and elotinib with or without growth 
factors (IGF1 100 nM, EGF 30 nM and VEGF 50 ng/ml) for 
72 h (30). Control cells were treated with vehicle alone 
(DMSO). After incubation, the revealing solution was 
added, and the luminescent output (relative luminescence 
units (RLUs)) was recorded using the Envision 
Multilable Reader (Perkin Elmer). Results are expressed 
as mean value ± standard error percentage RLU vs the 
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vehicle-treated control cells from three independent 
experiments in six replicates.
Caspase activation
Caspase activity was measured using Caspase-Glo 3/7 
assay (Promega), as previously described (31). Briefly, 
2 × 104 cells/well were seeded in 96-well black plates and 
treated with the indicated compounds for 72 h. Then, the 
Caspase-Glo 3/7 reagent was added at room temperature 
directly to the cell culture plates, which were then shaken 
at 12.7 g for 30 s, incubated for 1 h and measured for 
luminescent output (relative luminescence unit (RLU)) 
using the Envision Multilabel Reader (Perkin Elmer). 
Results are expressed as mean value ± s.e.m. percentage RLU 
vs vehicle-treated control cells from three independent 
experiments in six replicates.
3D model
3D spheroids were obtained as previously described (32). 
Briefly, 30 μL of cells suspension with 2.4 × 103 cells per well 
in an ultra-low attachment 96-well plate (Corning 96-well 
Clear Round Bottom Ultra-Low Attachment Microplate, 
NY, USA) in RPMI complete medium. After seeding, the 
plates were centrifuged at 300 g for 3 min. Plates were 
treated with the indicated compounds 72 h after seeding.
Human BP-NEN tissues collection and 
primary culture
Samples were derived from nine patients diagnosed with 
BP-NEN, whose characteristics are shown in Table  1 
(four females and five males; age = 21/81, mean = 50.44; 
ES ± 7.14), as previously described with minor modifications 
(30). All patients underwent surgical resection, and all 
had histological and immunohistochemical diagnosis 
of BP-NENs, according to the WHO classification. 
Primary cultures were prepared as previously described 
and treated with the indicated compounds (31, 32, 33). 
In order to prevent fibroblast overgrowth and subsequent 
cell viability decrease, which is observed after 4  days 
of culture, experiments were performed within 3  days. 
All the primary culture experiments were performed in 
accordance with the regulation of the University of Ferrara. 
The study was approved by the University of Ferrara 
Ethics Committee. Informed consents were obtained 
for disclosing clinical investigation and performing the 
in vitro study, in accordance with the local ethical committee.
Kinase activity assay
Phosphorylated EGFR (p-Tyr1068) and IGFR 
(p-Y1135/1136), p-VEGFR 2 (Tyr1175) levels were 
measured using the AlphaScreen SureFire assays 
(Perkin Elmer). Briefly, 2 × 104 cells/well were seeded in 
complete medium, in 96-well plates and, after overnight 
attachment, were incubated for 24 h with or without 
sunitinib and EGF, alone and in combination, or sunitinib 
and IGF1, alone or in combination. AlphaScreen SureFire 
assays were performed as previously described (30), and 
evaluated as per the manufacturer’s protocol. The plates 
were measured on an Envison plate reader (Perkin Elmer), 
using standard AlphaScreen settings, and the output was 
recorded as counts per second (cps).
Live/dead cells assay
Viability or cell death was determined using the Ready 
Probes Cell Viability Imaging Kit (Blue/Green) (Life 
Technologies). BP-NEN spheroids were treated with the 
indicated compounds 3  days after seeding. Seventy-two 
hours after treatment, 100 μL of cell stain mix (two drops 
of each stain per mL of culture media) was added to each 
well and incubated for 15 min. The different luminescence 
was observed using the EVOS FL Cell imaging System 
(Thermo Fisher Scientific). Fluorescence intensity was 
measured using ImageJ software.
Statistical analysis
Results are expressed as the mean ± s.e.m. Statistical analyses 
were carried out using ANOVA after proof of homogeneity 
of variances and normality tests, Tukey’s test was used 
for multiple comparisons. Data were analysed using 
GraphPad (Prism v-7.0); P values <0.05 were considered 
significant (*). For all the other experiments, if not 
otherwise indicated, Student’s paired or unpaired t-test 
Table 1 BP-NEN patients.
No. Sex Age Dimension (mm) Histology
1 F 61 190 Typical carcinoid
2 F 21 140 Typical carcinoid
3 M 24 300 Typical carcinoid
4 M 69 18 Typical carcinoid
5 M 43 350 Atypical carcinoid
6 M 33 120 Typical carcinoid
7 F 53 9 × 10 × 5 Typical carcinoid
8 F 69 22 × 7 × 20 Typical carcinoid
9 M 81 10 × 5 × 4 Atypical carcinoid
10 F 57 330 Typical carcinoid
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was used to evaluate the individual differences between 
the means, and P values <0.05 were considered significant.
Results
Influence of EGF, IGF1, VEGF and sunitinib on BP-NEN 
cell lines viability and caspase activation in 2D and 
3D culture systems
In order to understand how treatments with sunitinib 
and growth factors can influence cell viability and caspase 
activation of NCI-H720 and NCI-H727 cells, we performed 
viability and caspase activation assays using 2D system 
culture model. NCI-H720 and NCI-H727 cells were treated 
with EGF 30 nM, VEGF 50 ng/mL, IGF1 100 nM and/or 
sunitinib 5 μM. The concentration of sunitinib was chosen 
on the basis of preliminary experiment (data non shown), 
while growth factors concentration was chosen based on 
patients reported plasma concentration (25). As shown 
in Fig. 1A, EGF and VEGF did not affect cell viability of 
NCI-H720, while IGF1 significantly increased this 
parameter by 11% (P < 0.05 vs vehicle-treated cells). 
Sunitinib decreased cell viability by 40% (P < 0.05 vs 
vehicle cells). EGF and VEGF did not influence the effect 
of sunitinib, while IGF1 was able to counteract the 
antiproliferative effects of sunitinib (P < 0.05 vs sunitinib-
treated cells). In NCI-H727 cells, VEGF did not affect cell 
viability, while both EGF and IGF1 significantly increased 
this parameter by 10 and 15% respectively (P < 0.05 vs 
vehicle cells). Sunitinib decreased cell viability by 20% 
(P < 0.05 vs vehicle cells). VEGF did not influence the effect 
of sunitinib that was instead decreased by co-treatment 
with IGF1 and EGF (P < 0.05 vs sunitinib-treated cells).
In order to verify if the modulation of cell viability 
was also due to apoptosis, caspase 3/7 activation was 
evaluated. As shown in Fig. 1B, in NCI-H720 cells, none of 
the growth factors was able to significantly affect caspase 
3/7 activation while 5 μM sunitinib was able to increase 
the apoptotic activity by 100% (P < 0.05 vs vehicle cells). 
On the other hand, this effect was partially affected by 
IGF1 (−34% vs sunitinib-treated cells). In NCI-H727 cells 
(Fig.  1B), EGF was able to significantly reduce caspase 
3/7 activity by 13%. Sunitinib increased the apoptotic 
activation by 22% (P < 0.05 vs vehicle cells); however, this 
effect was significantly abrogated by co-treatment with 
both EGF and IGF1.
Moreover, we have cultured BP-NEN cell lines in 3D 
in order to observe the possible changes in cell viability/
death in a more realistic solid tumour model using two 
different fluorescent dyes. As shown in Fig. 1C, NCI-H720 
and NCI-H727 spheroids treated with sunitinib were 
characterised by a stronger green fluorescence, mostly 
focused in the middle of the spheroid, in comparison with 
cells treated with vehicle solution and growth factors. 
Green fluorescence (which indicates cell death) was 
evaluated, and the results overlap with those obtained 
with cell viability assay (Fig. 1D). The predominance of 
green fluorescence indicates a more extensive cell death 
in spheroids treated with sunitinib counteract at least in 
part by co-treatment with growth factors.
Influence of EGF, IGF1 and sunitinib on BP-NEN 
primary cell lines viability and caspase activation
In order to verify data obtained in immortalised cell 
lines in primary tumours, we tested the effects of EGF 
and IGF1 on cell viability in BP-NEN primary cultures. 
As shown in Fig. 2A, EGF 30 nM was able to increase cell 
viability, and partially counteract the effects of sunitinib 
in reducing of cell viability. Similarly, IGF1 (Fig. 2B) was 
able to significantly increase cell viability (P < 0.05) and to 
counteract, at least partially, the effects of sunitinib.
As concerns apoptotic activation (Fig. 2C and D), both 
EGF and IGF1 were able to significantly counteract caspase 
3/7 activity promoted by 5 μM sunitinib (P < 0.00001).
Effects of sunitinib on EGFR and 
IGF1R phosphorylation
To further investigate the mechanisms of action by 
which sunitinib exerts its effects on BP-NEN cells, 
phosphorylation levels of EGFR and IGF1R were evaluated 
by a kinase activity assay. Results concerning EGFR 
phosphorylation after treatments were not univocal 
(Fig. 3A). On the other hand, as shown in Fig. 3B, sunitinib 
was able to significantly decrease IGF1R phosphorylation 
levels and its co-treatment with the corresponding growth 
factor IGF1 partially restored receptor phosphorylation. 
pVEGFR2 levels were evaluated after treatment with 
sunitinib on primary culture, however, a modest and not 
significant reduction was observed in all sample analysed.
Influence of erlotinib and linsitinib on BP-NEN cell 
viability and caspase activation
Since our data indicate that EGF and IGF1 influence 
sunitinib activity, we assessed cell viability and caspase 
activation using erlotinib, an EGFR inhibitor and 
linsitinib, an IGF1R inhibitor, on NCI-H720 and NCI-H727 
cells. Cells were treated with erlotinib 5 μM alone and in 
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Figure 1
Effects of sunitinib and growth factors on cell viability, caspase activation and spheroids structure in human BP-NEN cell lines. NCI-H720 and NCI-H727 
cells were incubated in 96-well plates for 72 h in culture medium supplemented with 5 μM sunitinib or/plus IGF1 100 nM, EGF 30 nM and VEGF 50 ng/ml; 
control cells were treated with a vehicle solution. (A) Cell viability was measured as luminescent output in three independent experiments with six 
replicates each, and it is expressed as the mean ± s.e.m. *P < 0.05 vs vehicle cells; #P < 0.05 vs cells treated with sunitinib. (B) Caspase activity was 
measured as luminescent output in three independent experiments with six replicates each, and it is expressed as the mean ± s.e.m. *P < 0.05 vs vehicle 
cells; #P < 0.05 vs cells treated with sunitinib. (C) Representative spheroids pictures were taken with EVOS FL Cell imaging System 72 h after treatment. 
NCI-H720 and NCI-H727 cells spheroids were treated as described earlier; pictures were taken without and with the fluorescent staining. The second and 
fourth columns in each plot represent the merge between the two fluorescence detected. The blue dye stains the nuclei of all cells (excitation/emission 
maxima: 360/460 nm), while the green dye stains only the nuclei of dead cells with compromised plasma membranes (excitation/emission maxima: 
504/523 nm). (D) Green fluorescence from spheroids was analysed using ImageJ software.
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combination with linsitinib 5 μM. As shown in Fig.  4A, 
erlotinib and linsitinib showed an antiproliferative action 
in both cell lines. Erlotinib decreased cell viability of both 
cell lines by ~about a 20% (P < 0.01 vs vehicle cells) while 
treatment with linsitinib was able to reduce cell viability 
by 30% (P < 0.001 vs vehicle cells). The combination of 
the two agents showed a greater effect in comparison 
with single treatments in both NCI-H720 and NCI-H727 
cells reducing cell viability by ~ 40% vs vehicle-treated 
cells and by 20% vs treatment with erlotinib (P < 0.05 for 
NCI-H727 and P < 0.01 for NCI-H720 cells).
With regard to caspase activation, treatment 
with erlotinib did not significantly affect apoptosis in 
NCI-H720 cells, while linsitinib caused a significant 
increase by 40% (P < 0.01% vs vehicle cells). The 
combination of the two agents strongly activated caspase 
causing an increase of the 250% vs vehicle cells (P < 0.01).
In NCI-H727 cells, caspase activation was significant 
vs vehicle cells for both erlotinib and linsitinib alone and 
the combination of the two agents resulted in an increase 
in caspase activation of 300% (P < 0.01% vs vehicle cells). 
In both cell lines, the combination of erlotinib and 
Figure 2
Effects of sunitinib and growth factors on cell 
viability and caspase activation in human BP-NEN 
primary cultures. Cells were derived from patients 
samples and incubated in 96-well plates for 48 h 
in culture medium supplemented with 5 μM 
sunitinib or/plus EGF 30 nM (A and C) and IGF1 
100 nM (B and D); control cells were treated with 
a vehicle solution. (A and B) Cell viability was 
measured as luminescent output and evaluated 
in one experiment with six replicates; each point 
represents the mean of single sample. Data are 
expressed as the mean ± s.e.m. *P < 0.05, 
****P < 0.0001 vs CT. (C and D) Caspase activity 
was measured as a luminescent output and 
evaluated in one experiment with six replicates 
each point represents the mean of single sample. 
Data are expressed as the mean ± s.e.m. 
****P < 0.0001; ***P < 0.001 vs CT; ####P < 0.00001 
vs cells treated with sunitinib.
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Figure 3
Evaluation of phosphorylated EGFR and IGF1R in primary cultures after treatments. (A and B) Cells were treated with sunitinib 5 μM or/plus EGF 30 nM (A) 
and IGF1 100 nM (B). Cells were incubated for 24 h and control cells were treated with a vehicle solution. (A) Primary culture cells were lysed and 
processed for phosphorylated EGFR SureFire assays in one experiment with three replicates; in each graph is shown the global mean. Data are expressed 
as percentage of p-EGFR vs the control, considering as the control sample the untreated primary culture cells. (B) Primary culture cells were lysed and 
processed for phosphorylated IGF1R SureFire assays in one experiment with six replicates; in each graph is shown the global mean. Data are expressed 
as percentage of p-IGF1R vs vehicle-treated cells. (C) Primary culture cells were lysed and processed for phosphorylated VEGFR2 SureFire assays in one 
experiment with six replicates; in each graph is shown the global mean. Data are expressed as percentage of p-VEGFR vs vehicle-treated cells.
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linsitinib, significantly improve the activation of caspase 
3/7 as compare to both single agent (P < 0.001).
Furthermore, we cultured BP-NEN cell lines in 3D 
in order to observe the possible changes in cell viability/
death in a more realistic solid tumour model using 
two different fluorescent dyes. As shown in Fig.  1C, 
NCI-H720 and NCI-H727 spheroids treated with erlotinib 
and linsitinib were characterised by a stronger green 
fluorescence in comparison with cells treated with vehicle 
solution. Green fluorescence (which indicate cell death) was 
evaluated, and the results overlap with those obtained with 
cell viability assay (Fig. 4D). In order to confirm this data, 
we performed erlotinib and linsitinib treatment in BP-NEN 
primary culture, as shown in Fig. 5 both agents were able 
to reduce cell viability (P < 0.01) and to induce caspase 3/7 
activation (significantly just for erlotinib P < 0.01).
Discussion
BP-NENs are a group of malignancies increasing in 
incidence without a specific/effective therapeutic strategy 
(27). Everolimus is the only available molecular targeted 
therapy approved for this malignancy but recurrence of 
resistance after a period of treatment has already been 
demonstrated (21). Sunitinib, a small multi-RTKs inhibitor, 
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Figure 4
Effects of erlotinib and linsitinib on cell viability, caspase activation and spheroids structure in human BP-NEN cell lines. NCI-H720 and NCI-H727 cells 
were incubated in 96-well plates for 72 h in culture medium supplemented with 5 μM erlotinib and/or 5 μM linsitinib; control cells were treated with a 
vehicle solution. (A) Cell viability was measured as luminescent output in three independent experiments with six replicates each, and it is expressed as 
the mean ± s.e.m. *P < 0.05 vs vehicle cells or erlotinib; **P < 0.01 vs vehicle cells or erlotinib; ***P < 0.001 vs vehicle cells or erlotinib; ****P < 0.0001 vs 
vehicle cells or erlotinib. (B) Caspases activity was measured as luminescent output in three independent experiments with six replicates each and it is 
expressed as the mean ± s.e.m. *P < 0.05 vs vehicle cells or erlotinib; **P < 0.01 vs vehicle cells or erlotinib; ***P < 0.001 vs vehicle cells or erlotinib; 
****P < 00001 vs vehicle cells or erlotinib. (C) Representative spheroids pictures were taken with EVOS FL Cell imaging System 72 h after treatment. 
NCI-H720 and NCI-H727 were treated as described above; pictures were taken without and with the fluorescent staining. The second and fourth columns 
in each plot represent the merge between the two fluorescence dyes detected. The blue dye stains the nuclei of all cells (excitation/emission maxima: 
360/460 nm) while the green dye stains only the nuclei of dead cells with compromised plasma membranes (excitation/emission maxima: 504/523 nm). 
(D) Green fluorescence from spheroids was analysed using ImageJ software.
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has been approved for the treatment of some NENs such 
as pancreatic neuroendocrine neoplasms (23). Even if 
during sunitinib phase I and II clinical trials several NENs 
have been included, such as BP-NENs, during phase III, 
only patients with well-differentiated pancreatic endocrine 
tumours were included (34). Previously published evidence 
demonstrated the efficacy of sunitinib on GEP-NEN cell 
lines and primary culture (35, 36). However, the lack of 
data about sunitinib’s action and effectiveness in NENs 
of extra-pancreatic origin leads to the crucial necessity to 
study in vitro the possible role of sunitinib on BP-NENs 
and identify possible markers that may be useful in the 
treatment of a malignancy lacking of original designed 
trials. In this study, we have shown for the first time the 
effects of Sunitinib on BP-NEN using two cell lines and 
primary cultures. Our findings are consistent with other 
studies that have already demonstrated the efficacy of 
the drug also in malignancies for which sunitinib is not 
approved (25, 37). Our data suggest that EGF and IGF1 
may be involved in sunitinib mechanism of action since 
co-treatment with these factors counteracts, at least in 
part, the drug antiproliferative and pro apoptotic action. 
Therefore, VEGFR, described in literature as the main 
sunitinib target, may not represent a key regulator of its 
mechanism of action in BP-NEN. Our results also show 
how IGF1 significantly counteracts the effects of sunitinib 
on cell viability and caspase activation in both NCI-H720 
and NCI-H727 cells. This trend could also be observed in 
NCI-H727 cells with EGF and sunitinib combined treatment 
and, with less impact, on primary cultures. These findings 
are in contrast with literature where VEGFR is described 
as the main target of sunitinib. Only few studies have 
explored the possible involvement of others RTKs in the 
drug mechanism of action, whereas our data suggest IGF1R 
and EGFR as key target in BP-NENs (1, 38, 39). In addition, 
we employed a 3D culture system in order to better 
characterise the role of EGFR and IGF1R as key regulators 
of sunitinib mechanism of action. Impact of sunitinib and 
growth factors on three-dimensional cell structure and 
cell viability were evaluated using a staining assay and 
our findings indicate that even in a 3D system sunitinib 
has a strong antiproliferative effect that it’s focused in the 
centre of the spheroids. Furthermore, sunitinib effects 
have been deeply evaluated in primary cultures. The 
drug has been tested alone and in combination with EGF 
and IGF1 and our findings indicate that treatment with 
the drug decreases IGF1R phosphorylation levels that 
are partially restored with co-treatment with IGF1. 
On the other hand, the correlated experiments with 
sunitinib and EGF are not univocal probably due to the 
small number of available samples. Since our results 
indicated that IGF1R and EGFR are involved in modulating 
sunitinib effects, we decided to better characterise the 
role of these two receptors in regulating BP-NEN cell 
lines proliferation employing linsitinib and erlotinib, 
respectively, IGF1R and EGFR inhibitors. Results indicate 
that both erlotinib and linsitinib have an antiproliferative 
action on the two cell lines and that treatments generate 
a strong caspase activation.
Our findings indicated also that the combination 
of erlotinib and linsitinib decreased cell viability to a 
greater extent as compared to single treatments and to 
treatment with sunitinib. These results are mirrored 
by caspase activation that, particularly for NCI-H727 
cells, is induced by almost three fold as compared to 
treatments with linsitinib, erlotinib and even sunitinib 
alone. Analysis of 3D spheroids structure and cell viability 
revealed that these drugs seem to act mostly in the 
centre of the spheroids and that linsitinib and erlotinib 
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Figure 5
Effects of erlotinib and linsitinib on cell viability, caspase activation in 
human BP-NEN primary culture. Cells were incubated in 96-well plates for 
72 h in culture medium supplemented with 5 µM erlotinib, 5 µM linsitinib, 
IGF1 100 nM or EGF 30 nM; control cells were treated with vehicle 
solution. (A) Cell viability was measured as luminescent output in three 
independent experiments with six replicates each, and it is expressed as 
the mean ± s.e.m. **P < 0.01, ***P < 0.001 vs vehicle-treated cells. (B) 
Caspases activity was measured as luminescent output in three 
independent experiments with six replicates each and it is expressed as 
the mean ± s.e.m. **P < 0.01 vs vehicle-treated cells.
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decrease cell viability with a greater effect in combination. 
The importance of EGFR and IGF1R in NENs treatment 
is supported by several hypotheses. Gilbert et  al. have 
demonstrated that NENs samples derived from patients 
exhibit high EGFR levels and that high IGF1R levels are 
present in BP-NEN cell lines (40, 41). Erlotinib decrease 
NCI-H720 cell viability of a 20% and its effect is visible 
also in caspase activation (+20%) even if the result is not 
significant. This can be due to the small, but still present, 
effect of erlotinib in this cell line. Moreover, erlotinib 
effect is evident once in combination with linsitinib; their 
combined effect is stronger than the single treatment 
of both drugs underling a synergistic effect of the two 
agents. The synergistic effect of linsitinib and erlotinib 
is particularly important for NCI-H727, as these cells 
have been shown to be resistant to Everolimus and NVP-
BEZ235 (30) and they show limited response to sunitinib 
as compare to NCI-H720 (Fig. 1A).
Therefore, in this case, EGFR and IGF1R are suggested 
as new potential targets useful for the development of 
new therapies in NENs. Moreover, the double inhibition 
induced by co-treatments with erlotinib and linsitinib 
could lead to the block of the well-established reciprocal 
cross-talk between EGFR and IGF1R. This relation 
has been previously demonstrated by Haluska et  al. to 
induced in many cancer types the adaptive activation of 
IGF1R family members upon the inactivation of EGFR 
and vice versa (42). These authors also showed that in 
ovarian and breast cancer cell lines, the co-treatment 
with IGF1R and EGFR inhibitors results in a synergic 
antiproliferative effect followed by the decrease of several 
important proteins involved in cancer progression, 
morphological changes and caspase activation in 
comparison to single treatments. These results are in 
agreement with our findings supporting the hypothesis 
that more specific RTK inhibitors could be important in 
the management of NENs characterised by IGF1R and 
EGFR overexpression.
Our results show for the first time the effectiveness 
of sunitinib in BP-NENs cells and that the VEGF/VEGFR 
system may not be crucial in modulating BP-NENs 
responsiveness to the drug. Evidence that IGF1 and EGF 
counteract sunitinib action indicates that IGF1R and EGFR 
may be key regulators of sunitinib resistance that might 
be overcome using a combination of more specific IGF1R 
and EGFR inhibitors. In conclusion, our data suggest that 
RTKs inhibition can open new therapeutic horizons in 
BP-NENs treatment and that specific targets need to be 
inhibited to overcome resistance.
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